Navigation Links
3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Date:7/10/2012

MENLO PARK, Calif., July 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula Hotel in New York City.  Dr. Kemble will provide an overview of 3-V, including a discussion of both its lead program targeting the fatty acid synthase (FASN) pathway for the treatment of chronic hepatitis C virus (HCV) infection and the company's discovery platform.  Dr. Kemble's presentation will take place on Friday, July 13 at 12:00pm.

FASN is a cellular enzyme with increased expression following infection with HCV and in several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become potent therapeutics for chronic HCV and other indications.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information Stephen R. Brady Chief Business Officer 650-561-8600


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Delcath To Present At JMP Securities Healthcare Conference On July 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing platform that ... the 2017 Women’s Choice Award. The identification by women of an effective new ... migraine sufferers are women. In a survey taken by the Women’s Choice Award organization, ...
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS Healthcare Solutions, a leading ... a new professional fee E/M leveling calculator tool. The new resource is offered ... E/M coding is complex which supports the need for a tool of this ...
(Date:8/22/2017)... ... 22, 2017 , ... “Without Love’s Beauty and Pleasures Life ... struggles faced while hoping for a better life. “Without Love’s Beauty and Pleasures ... who spent 13 years working with deprived/neglected adolescents and almost 20 years working ...
(Date:8/22/2017)... ... , ... “Call Of Spiritual Duty”: a revelation in an era defined by ... Growing up on the streets of North Visalia, California, Carlos Lizarde quickly became ... Biblical keys to his life, he noticed immediately that opportunities and blessings began to ...
(Date:8/21/2017)... Los Angeles, California (PRWEB) , ... August 21, ... ... Physicians is announcing the addition of two plastic surgery fellows for academic year ... is designed for candidates who have successfully completed residency in Plastic and Reconstructive ...
Breaking Medicine News(10 mins):